Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
NCT ID: NCT05399485 Phase: PHASE3 Status: COMPLETED Enrollment: 496 Completion: 2024-11-07
Conditions
Migraine
Interventions
Rimegepant, Placebo
Summary
This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.
Primary Outcome
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase